Business
Genflow Biosciences PLC Announces Half-Year Report
LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025. Chairman's Statement It is my pleasure to update shareholders ...
About this update from Genflow Biosciences Plc
[{"type":"text","content":"LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.","length":185,"tagName":"p"},{"type":"text","content":"Chairman's Statement","length":24,"tagName":"p"},{"type":"text","content":"It is my pleasure to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on our performance during the first six months of 2025.","length":172,"tagName":"p"},{"type":"text","content":"As of 30 June 2025, Genflow has made important progress across its programs in both human health and animal health, advancing our mission to extend healthspan through our proprietary SIRT6 centenarian-based gene therapies. These two dimensions of our pipeline are deeply complementary: our human programs target age-related diseases with high unmet need, while our veterinary initiatives allow us to generate translational data, demonstrate safety and feasibility, and explore commercial opportunities in the growing companion animal health sector.","length":548,"tagName":"p"},{"type":"text","content":"Human Health Pipeline","length":21,"tagName":"p"},{"type":"text","content":"In human health, our pipeline spans MASH ("Metabolic Dysfunction-Associated Steatohepatitis"), sarcopenia, Werner Syndrome, and exploratory programs in ophthalmology. Collectively, these programs highlight the versatility of SIRT6 centenarian in addressing fundamental mechanisms of aging across multiple systems.","length":323,"tagName":"p"},{"type":"text","content":"The most notable development has been in MASH. Recent approvals of two new therapies including GLP-1 agonists have provided effective therapies for patients in the earlier stages of disease (approximately two-thirds of the population). However, there remains a profound unmet need in advanced MASH with fibrosis, where therapeutic options are extremely limited. In response, Genflow has repositioned GF-1002 to target this high-need population (around one-third of patients). With its antifibrotic properties and potential to prevent progression to liver cancer, GF-1002 is uniquely suited to address this stage of disease. While the patient population is smaller, the commercial opportunity is significant, given the lack of alternatives beyond liver transplanta...